Imatinib was first approved by the FDA for the treatment of patients with soft tissue tumors bearing COL1A1–PDGFB fusion in 2006 and, according to a recent systematic review, was associated with objective responses in more than 60% of advanced cases (20). This evidence concerns the gene PDGFB and soft tissue neoplasm.